{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:57:00Z","timestamp":1761901020494,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.msard.2014.07.001","type":"journal-article","created":{"date-parts":[[2014,7,21]],"date-time":"2014-07-21T14:04:33Z","timestamp":1405951473000},"page":"659-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immune reconstitution inflammatory syndrome and natalizumab\u2013Is it possible before removing the drug?"],"prefix":"10.1016","volume":"3","author":[{"given":"P.","family":"Mulero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Neri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.F.","family":"Arenillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2014.07.001_bib10","doi-asserted-by":"crossref","first-page":"e52208","DOI":"10.1371\/journal.pone.0052208","article-title":"Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis","volume":"7","author":"Benkert","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2014.07.001_bib1","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/1352458507087135","article-title":"Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy","volume":"14","author":"Berger","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2014.07.001_bib6","doi-asserted-by":"crossref","unstructured":"Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S; on behalf of the TYSABRI Observational Program (TOP) Investigators. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014 Feb 14. [Epub ahead of print]","DOI":"10.1136\/jnnp-2013-306936"},{"key":"10.1016\/j.msard.2014.07.001_bib4","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies. Results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2014.07.001_bib8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/NEN.0b013e31825caf2c","article-title":"Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab","volume":"71","author":"Kleinschmidt-DeMasters","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"issue":"11","key":"10.1016\/j.msard.2014.07.001_bib7","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1177\/1352458509107011","article-title":"Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis","volume":"15","author":"Rinaldi","year":"2009","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.msard.2014.07.001_bib9","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.4049\/jimmunol.155.6.2938","article-title":"Role of the VLA-4 molecule in T cell costimulation. Identification of the tyrosine phosphorylation pattern induced by the ligation of VLA-4","volume":"155","author":"Sato","year":"1995","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.msard.2014.07.001_bib3","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1212\/WNL.0b013e3182840be3","article-title":"Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies","volume":"80","author":"Svenningsson","year":"2013","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.msard.2014.07.001_bib2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jns.2010.01.001","article-title":"A giant MS plaque mimicking PML during natalizumab treatment","volume":"291","author":"Twyman","year":"2010","journal-title":"J Neurol Sci"},{"issue":"10","key":"10.1016\/j.msard.2014.07.001_bib5","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00115-011-3319-2","article-title":"Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology","volume":"82","author":"Warnke","year":"2011","journal-title":"Nervenarzt"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034814000674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034814000674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:35:55Z","timestamp":1761899755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034814000674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S2211034814000674"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2014.07.001","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune reconstitution inflammatory syndrome and natalizumab\u2013Is it possible before removing the drug?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2014.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}